Literature DB >> 21148070

Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases.

Jason M Bodily1, Kavi P M Mehta, Laimonis A Laimins.   

Abstract

Infection by human papillomaviruses (HPV) leads to the formation of benign lesions, warts, and in some cases, cervical cancer. The formation of these lesions is dependent upon increased expression of proangiogenic factors. Angiogenesis is linked to tissue hypoxia through the activity of the oxygen-sensitive hypoxia-inducible factor 1α (HIF-1α). Our studies indicate that the HPV E7 protein enhances HIF-1 transcriptional activity whereas E6 functions to counteract the repressive effects of p53. Both high- and low-risk HPV E7 proteins were found to bind to HIF-1α through a domain located in the N-terminus. Importantly, the ability of E7 to enhance HIF-1 activity mapped to the C-terminus and correlated with the displacement of the histone deacetylases HDAC1, HDAC4, and HDAC7 from HIF-1α by E7. Our findings describe a novel role of the E7 oncoprotein in activating the function of a key transcription factor mediating hypoxic responses by blocking the binding of HDACs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21148070      PMCID: PMC3077548          DOI: 10.1158/0008-5472.CAN-10-2626

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

Review 1.  Papillomaviruses in human cancers.

Authors:  H zur Hausen
Journal:  Proc Assoc Am Physicians       Date:  1999 Nov-Dec

2.  Suppression of cyclin D1 by hypoxia-inducible factor-1 via direct mechanism inhibits the proliferation and 5-fluorouracil-induced apoptosis of A549 cells.

Authors:  Wen Wen; Jin Ding; Wen Sun; Kun Wu; Beifang Ning; Wenfeng Gong; Guoping He; Shanna Huang; Xinyu Ding; Peipei Yin; Lei Chen; Qiong Liu; Weifen Xie; Hongyang Wang
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

Review 3.  Biological activities and molecular targets of the human papillomavirus E7 oncoprotein.

Authors:  K Münger; J R Basile; S Duensing; A Eichten; S L Gonzalez; M Grace; V L Zacny
Journal:  Oncogene       Date:  2001-11-26       Impact factor: 9.867

4.  Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein.

Authors:  Alexandra Eichten; Matthew Westfall; Jennifer A Pietenpol; Karl Münger
Journal:  Virology       Date:  2002-03-30       Impact factor: 3.616

Review 5.  Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors.

Authors:  Daniel J Brat; Balveen Kaur; Erwin G Van Meir
Journal:  Front Biosci       Date:  2003-01-01

6.  Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.

Authors:  L Zhang; D Yu; M Hu; S Xiong; A Lang; L M Ellis; R E Pollock
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

7.  Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes.

Authors:  M S Kim; H J Kwon; Y M Lee; J H Baek; J E Jang; S W Lee; E J Moon; H S Kim; S K Lee; H Y Chung; C W Kim; K W Kim
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

8.  The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression.

Authors:  Fabiana Schwartzenberg-Bar-Yoseph; Michal Armoni; Eddy Karnieli
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

9.  The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papillomavirus type 31.

Authors:  Michelle S Longworth; Laimonis A Laimins
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors.

Authors:  Esra Toussaint-Smith; David B Donner; Ann Roman
Journal:  Oncogene       Date:  2004-04-15       Impact factor: 9.867

View more
  68 in total

Review 1.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

Review 2.  Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.

Authors:  Teresa C Longoria; Krishnansu S Tewari
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

Review 3.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

Review 4.  Towards incorporating epigenetic mechanisms into carcinogen identification and evaluation.

Authors:  Zdenko Herceg; Marie-Pierre Lambert; Karin van Veldhoven; Christiana Demetriou; Paolo Vineis; Martyn T Smith; Kurt Straif; Christopher P Wild
Journal:  Carcinogenesis       Date:  2013-06-07       Impact factor: 4.944

5.  Epigenetics of human papillomaviruses.

Authors:  Eric Johannsen; Paul F Lambert
Journal:  Virology       Date:  2013-08-13       Impact factor: 3.616

6.  Productive replication of human papillomavirus 31 requires DNA repair factor Nbs1.

Authors:  Daniel C Anacker; Dipendra Gautam; Kenric A Gillespie; William H Chappell; Cary A Moody
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

Review 7.  Molecular mechanisms of human papillomavirus-related carcinogenesis in head and neck cancer.

Authors:  Farhoud Faraji; Munfarid Zaidi; Carole Fakhry; Daria A Gaykalova
Journal:  Microbes Infect       Date:  2017-06-12       Impact factor: 2.700

8.  Human papillomavirus type 16 E7 oncoprotein upregulates the retinoic acid receptor-beta expression in cervical cancer cell lines and K14E7 transgenic mice.

Authors:  Jorge Gutiérrez; Enrique García-Villa; Rodolfo Ocadiz-Delgado; Enoc M Cortés-Malagón; Juan Vázquez; Alejandra Roman-Rosales; Elizabeth Alvarez-Rios; Haydar Celik; Marta C Romano; Aykut Üren; Paul F Lambert; Patricio Gariglio
Journal:  Mol Cell Biochem       Date:  2015-07-15       Impact factor: 3.396

9.  A compendium of proteins that interact with HIF-1α.

Authors:  Gregg L Semenza
Journal:  Exp Cell Res       Date:  2017-03-20       Impact factor: 3.905

10.  Improved survival with bevacizumab in advanced cervical cancer.

Authors:  Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.